rGM-CSF and rGM-CSF/rIL-4 increased the percentage of myeloid DCs (CD11c⁺/CD11b⁺) in spleen, but only rGMCSF/rIL-4 increased the percentage of lymphoid DCs (CD11c⁺/CD8α⁺).

Mice were treated with rGM-CSF (GM) or the combination of rGM-CSF/rIL-4 (GM/IL-4), as described for Figure 1. Spleen cells were isolated on day 7, and FACS analysis was performed to determine the percentage of total spleen cells expressing either a myeloid DC phenotype (upper panel, stained with CD11b-PE and CD11c-FITC) or a lymphoid phenotype (middle panel, stained with CD8α-PerCP and CD11c-FITC). The percentage of cells expressing DEC-205, another lymphoid DC marker, were also determined (lower panel, stained with CD11c-PE and DEC-205-FITC). The percentage of double-stained cells for each marker set are identified. Results are from a single representative experiment (n > 20).